期刊文献+

肥厚型心肌病的诊断与治疗进展 被引量:3

Advances in Diagnosis and Treatment of Hypertrophic Cardiomyopathy
下载PDF
导出
摘要 肥厚型心肌病是一种常见的常染色体显性遗传性心肌疾病,是青年人最常引起心源性猝死的原因。应结合临床表现、影像学检查及基因检测充分诊断肥厚型心肌病。肥厚型心肌病的治疗应遵循个体化原则,选择合理的药物或者外科或导管消融手术治疗策略。 Hypertrophic cardiomyopathy is a common autosomal dominant hereditary heart disease which is also the most common cause of sudden cardiac death among young people. Clinical manifestations, imaging and genetic testing should be combined with to fully diagnose hypertrophic cardiomyopathy. The treatment of hypertrophic cardiomyopathy would be followed the principle of individual, and rational drug or surgical or catheter ablation treatment strategy need to be selected.
出处 《心血管病学进展》 CAS 2013年第5期686-689,共4页 Advances in Cardiovascular Diseases
关键词 肥厚型心肌病 基因检测 诊断 治疗 hypertrophic cardiomyopathy genetic testing diagnosis treatment
  • 相关文献

参考文献28

  • 1Christiaans I, Birnie E, Bonsel GJ, et al. Manifest disease, risk factors for sud- den cardiac death, and cardiac events in a large nationwide cohort of predictive- ly tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy [ J ]. Eur Heart J, 2011,32 ( 9 ) : 1161 - 1170.
  • 2Papadakis M, Carre F, Kervio G, et al. The prevalence, distribution, and clin- ical outcomes of electrocardiographic repolarization patterns in male athletes of Africart/Afre-Caribbean origin[J]. Eur Heart J,2011,32(18) : 2304-2313.
  • 3Jansen MK, Havndrup O, Christiansen M ,et al. Penetrance of hypertrophic car- diomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing [ J ]. Circulation, 2013,127 ( 1 ) : 48- 54.
  • 4Maron B J, Rowin EJ, Casey SA, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy > = 60 years of age [ J ]. Circulation, 2013, 127 (5) : 585 -593.
  • 5Maron MS, Lesser JR, Maron BJ. Management implications of massive left van- trieular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance [ J ]. Am J Cardio1,2010,105 (12) : 1842-1843.
  • 6Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardlomyopathy [ ] ]. Circulation,2011,124 ( 1 ) :40-47.
  • 7Maron MS, Maren BJ, Harrigan C, et al. Hypertrophic eardiomyopathy pheno- type revisited after 50 years with cardiovascular magnetic resonance [ J ]. J Am Coil Cardiol,2009,54 : 220-228.
  • 8Gupta RM, Weiner RB, Baggish AL, et al. Still a kid at heart: hypertrophic cardiomyopathy in the elderly[J]. Circulation, 2011,124(7) :857-863.
  • 9Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the di- agnosis and treatment of hypertrophic cardiomyopathy : a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines[J]. J Thorac Cardiovasc Surg,2011,142(6) :e153-e203.
  • 10Basavarajaiah S, Boraita A, Whyte G, et al. Ethnic differences in left ventric- ular remodeling in highly-trained athletes relevance to differentiating physiologic left ventricular hypertrophy from hypertrophic cardiomyopathy[ J ]. J Am Coil Cardio1,2008,51 (23) :2256-2262.

同被引文献35

  • 1LEONARDI R A,TOWNSEND J C,PATEL C A,et al.Alcohol septal ablation for obstructive hypertrophiccardiomyopathy : outcomes in young, middle-aged, and elderlypatients[J]. Catheter Cardiovasc Interv, 2013,82(5): 838-845.
  • 2JENSEN M K,PRINZ C,HORSTKOTTE D, et al. Alcoholseptal ablation in patients with hypertrophic obstructivecardiomyopathy : low incidence of sudden cardiac death andreduced risk profile[J]. Heart, 2013, 99( 14) : 1012-1017.
  • 3LoPEZ-ABURTO G,PALACiOS-RODR GUEZ J M,CANT-RAM REZ S, et al. Septal alcohol ablation in patients withhypertrophic cardiomyopathy [J]. Rev Med Inst Mex SeguroSoc, 2013, 51(4): 396-401.
  • 4STEENDUK P,MELIGA E,VALGIMIGLI M,et al. Acuteeffects of alcohol septal ablation on systolic and diastolic leftventricular function in patients with hypertrophic obstructivecardiomyopathy [ J]. Heart, 2008,94( 10) : 1318-1322.
  • 5DABROWSKI M,CHOJNOWSKA L,MAE K, et al. Anassessment of regression of left ventricular hypertrophy followingalcohol ablation of the interventricular septum in patients withhypertrophic cardiomyopathy with left ventricular outflow tractobstruction[J]. Kardiol Pol, 2012, 70(8) : 782-788.
  • 6RIVERA S, SITGES M, AZQUETA M,et al. Left ventricularremodeling in patients with hypertrophic obstructivecardiomyopathy treated with percutaneous alcohol septalablation: an echocardiographic study [J]. Rev Esp Cardiol, 2003,56(12): 1174-1181.
  • 7WOJTAROWIGZ A,KORNACEWICZ-JACH Z,KA^MIERCZAKJ, et al. Doppler echocardiographic evaluation of left ventriculardiastolic function in patients with hypertrophic obstructivecardiomyopathy after alcohol septal ablation in acute and long-term follow up[J]. Pol Merkur Lekarski, 2002,13(73) : 25-28.
  • 8LEONARDI R A, KRANSDORF E P, SIMEL D L, et al.Meta-analyses of septal reduction therapies for obstructivehypertrophic cardiomyopathy : comparative rates of overallmortality and sudden cardiac death after treatment [J]. Circ Cardi-ovasc Interv, 2010, 3(2) : 97-104.
  • 9Williams LK, Gruner CH, Rakowski H. The role of echocardiography in hyper-trophic cardiomyopathy[ J]. Curr Cardiol Rep,2015 ,17(2) :6.
  • 10Elliott PM, Anastasakis A,Borger MA, et al. 2014 ESC guidelines on diagnosisand management of hypertrophic cardiomyopathy [ J ]. Kardiol Pol, 2014, 72(11):1054-1126.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部